Aurobindo Pharma Limited (AUROPHARMA)
Analysts/Institutional Investor Meet/Con. Call Updates
AI summary
- Q2FY27 revenue 10,263 Cr +24% y-y; Operating EBITDA 2,156 Cr +28% y-y; margin 21%
- US revenue USD 477 mn +25% y-y; 10 product launches, 7 ANDA filings, 12 approvals
- Europe revenue €288 mn +18% constant currency; growth markets USD 107 mn +16%
- FY27 guidance: double-digit revenue growth, EBITDA margin >21%, EBITDA >8,000 Cr
- FY28 outlook better with full Lannett benefit, China ramp-up, biosimilars growth
- Lannett profitable, integration progressing; CDMO opportunities cautious and selective
- Raleigh unit capacity low; inhaler and derma products ramping over next 6-9 months
- China facility breakeven expected this quarter; Pen-G plant positive EBITDA, ramping
- Biosimilars selective portfolio; focus on differentiated formats and partnerships
- Multiple analyst queries on margin trajectory and respiratory segment growth
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 AUROPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add AUROPHARMA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Aurobindo Pharma Limited
Important.
The summary above is generated automatically from Aurobindo Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.